国际标准期刊号: 2469-9764

工业化学:开放获取

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 参考搜索
  • 研究期刊索引目录 (DRJI)
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 学者指导
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
分享此页面

抽象的

Review Provides a Comprehensive Analysis of the Therapeutic Uses, Side Effects, Pharmacokinetics, and Drug Interactions Associated with a Selection of Painkillers and NSAIDs

Surabhi Sinha

Drug interactions are a critical consideration in healthcare, as they can significantly impact patient safety and treatment outcomes. This abstract focuses on the drug interactions of some commonly used painkillers, specifically nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are widely prescribed for their analgesic and anti-inflammatory properties, but they also carry the potential for interactions with other medications. Several factors contribute to the likelihood of drug interactions involving NSAIDs, such as their metabolism through specific liver enzymes and their ability to affect renal function. The interactions between NSAIDs and various classes of medications, including but not limited to anticoagulants, antiplatelet agents, corticosteroids, selective serotonin reuptake inhibitors (SSRIs), and diuretics. The mechanisms of these interactions are explored, elucidating the pharmacokinetic and pharmacodynamic aspects that underlie the potential adverse effects.

Understanding the potential drug interactions of NSAIDs is essential for healthcare professionals to ensure safe and effective pain management strategies. By identifying and managing these interactions, healthcare providers can minimize the risk of adverse effects, optimize therapeutic outcomes, and tailor treatment plans based on individual patient characteristics and concomitant medications. Aims to raise awareness about the importance of considering drug interactions when prescribing or administering NSAIDs and emphasizes the need for comprehensive medication reviews and monitoring to mitigate potential risks associated with polypharmacy and co-prescribing practices.